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Abstract
Microglia adopt numerous fates with homeostatic microglia (HM)
and a microglial neurodegenerative phenotype (MGnD) represent-
ing two opposite ends. A number of variants in genes selectively
expressed in microglia are associated with an increased risk for
neurodegenerative diseases such as Alzheimer’s disease (AD) and
frontotemporal lobar degeneration (FTLD). Among these genes are
progranulin (GRN) and the triggering receptor expressed on
myeloid cells 2 (TREM2). Both cause neurodegeneration by mecha-
nisms involving loss of function. We have now isolated microglia
from Grn/ mice and compared their transcriptomes to those of
Trem2/ mice. Surprisingly, while loss of Trem2 enhances the
expression of genes associated with a homeostatic state, microglia
derived from Grn/ mice showed a reciprocal activation of the
MGnD molecular signature and suppression of gene characteristic
for HM. The opposite mRNA expression profiles are associated with
divergent functional phenotypes. Although loss of TREM2 and
progranulin resulted in opposite activation states and functional
phenotypes of microglia, FDG (fluoro-2-deoxy-D-glucose)-lPET of
brain revealed reduced glucose metabolism in both conditions,
suggesting that opposite microglial phenotypes result in similar
wide spread brain dysfunction.
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Introduction
While for a long time researchers distinguished only two distinct
stages of microglia, the M1 and the M2 phenotype, recent evidence
strongly indicates that a multitude of functionally diverse microglial
populations exists in a dynamic equilibrium (Ransohoff, 2016;
Keren-Shaul et al, 2017; Krasemann et al, 2017). This becomes very
apparent when one compares mRNA signatures of microglia isolated
from various mouse models for neurodegeneration and compares
them to controls (Abduljaleel et al, 2014; Butovsky et al, 2015;
Holtman et al, 2015; Keren-Shaul et al, 2017; Krasemann et al,
2017). In mouse models for neurodegenerative diseases, mRNA
signatures were identified which are characteristic for a disease-
associated microglia (DAM)/a microglial neurodegenerative pheno-
type (MGnD) whereas in controls a homeostatic microglial (HM)
signature was observed (Butovsky et al, 2014, 2015; Holtman et al,
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2015; Keren-Shaul et al, 2017; Krasemann et al, 2017). MGnD
upregulates a characteristic set of genes, which may initially allow
microglia to respond to neuronal injury in a defensive manner. This
includes the induction of pathways triggering phagocytosis, chemo-
taxis/migration, and cytokine release. The upregulation of genes
involved in those pathways goes along with a suppression of home-
ostatic genes (Butovsky et al, 2015; Krasemann et al, 2017). Key
genes involved in the switch of HM to MGnD are regulated by the
TREM2 (triggering receptor expressed on myeloid cells 2) ApoE
(apolipoprotein E) pathway (Krasemann et al, 2017).
A pivotal role of microglia in neurodegeneration is strongly
supported by the identification of sequence variants found in a
number of genes robustly or even selectively expressed within
microglia in the brain, among them GRN (encoding the progranulin
(PGRN) protein; Baker et al, 2006; Cruts & Van Broeckhoven, 2008;
Zhang et al, 2014; Gotzl et al, 2016; Lui et al, 2016) and TREM2
(Guerreiro et al, 2013; Jonsson & Stefansson, 2013; Jonsson et al,
2013; Rayaprolu et al, 2013; Borroni et al, 2014; Cuyvers et al,
2014; Ulrich et al, 2017). Mutations in the GRN gene (Baker et al,
2006; Cruts et al, 2006) cause frontotemporal lobar degeneration
(FTLD) with TDP-43 (TAR-DNA binding protein 43)-positive inclu-
sions due to haploinsufficiency. PGRN is a growth factor-like protein
with neurotrophic properties in the brain (Van Damme et al, 2008).
PGRN is also transported to lysosomes (Hu et al, 2010; Zhou et al,
2015) where it appears to regulate expression and activity of lysoso-
mal proteins (Ahmed et al, 2010; Hu et al, 2010; Wils et al, 2012;
Tanaka et al, 2013a,b; Gotzl et al, 2014, 2016, 2018; Beel et al,
2017; Chang et al, 2017; Ward et al, 2017; Zhou et al, 2017). PGRN
is proteolytically processed into granulin peptides, which can be
found in biological fluids (Bateman et al, 1990; Shoyab et al, 1990;
Belcourt et al, 1993; Cenik et al, 2012). TREM2 is produced as a
membrane-bound type-1 protein (Kleinberger et al, 2014), which
traffics to the cell surface where it mediates signaling via binding to
its co-receptor, the DNAX activation protein of 12 kDa (DAP12;
Ulrich & Holtzman, 2016; Yeh et al, 2017). Signaling is terminated
by proteolytic shedding of the TREM2 ectodomain (Kleinberger
et al, 2014; Schlepckow et al, 2017). Several sequence variants
associated with TREM2 cause neurodegeneration via a loss of func-
tion (Kleinberger et al, 2014, 2017; Schlepckow et al, 2017; Ulland
et al, 2017; Song et al, 2018). Sequence variants of TREM2 affect a
multitude of functions including chemotaxis, migration, survival,
binding of phospholipids and ApoE, proliferation, survival, and
others (Kleinberger et al, 2014, 2017; Atagi et al, 2015; Bailey et al,
2015; Wang et al, 2015; Yeh et al, 2016; Mazaheri et al, 2017;
Ulland et al, 2017). Strikingly, a loss of TREM2 function locks microglia
in a homeostatic state (Krasemann et al, 2017; Mazaheri et al, 2017).
Instead of suppressing their homeostatic mRNA signature like mouse
models of neurodegenerative disorders, in the absence of TREM2
microglia even enhance expression of homeostatic genes and fail to
express the disease-associated signature (Krasemann et al, 2017; Maza-
heri et al, 2017). As a result, TREM2 deficiency decreases chemotaxis,
phagocytosis, and barrier function (Kleinberger et al, 2017; Mazaheri
et al, 2017; Ulland et al, 2017). TREM2 therefore appears to play a key
role as a central hub gene in the regulation of microglial homeostasis.
We now investigated microglial gene expression and function in the
absence of PGRN and made the surprising observation that loss of
TREM2 or PGRN leads to opposite microglial activity phenotypes,
which, however, both cause wide spread brain dysfunction.
Results
Opposite molecular signatures of microglia in Grn/ and
Trem2/ mice
Loss-of-function mutations in TREM2 are associated with various
types of neurodegeneration, including a FTLD-like syndrome (Ulrich
& Holtzman, 2016). Similarly, haploinsufficiency of GRN is associated
with TDP-43-positive FTLD (Baker et al, 2006; Cruts et al, 2006; Cruts
& Van Broeckhoven, 2008). At least some of the GRN-dependent
FTLD-associated phenotypes can be mimicked in a mouse model
entirely lacking PGRN (Ahmed et al, 2010; Yin et al, 2010; Wils et al,
2012; Gotzl et al, 2014). Furthermore, both, a Trem2 knockout and
the knockin of the p.T66M mutation, mimic features of a FTD-like
syndrome (Kleinberger et al, 2017; Mazaheri et al, 2017). Since both
proteins are preferentially expressed in microglia, we compared loss-
of-PGRN-associated microglial phenotypes with those known for
TREM2 deficiency (Krasemann et al, 2017; Mazaheri et al, 2017). To
do so, we first purified microglia from brains of adult Grn/ mice by
fluorescence-associated cell sorting (FACS) using microglia-specific
anti-FCRLS and anti-CD11b antibodies. We then investigated the
expression pattern of gene characteristic for MGnD and HM using
NanoString gene expression profiling (MG534; Butovsky et al, 2014;
Krasemann et al, 2017; Mazaheri et al, 2017; Dataset EV1). Gene
expression levels in each sample were normalized against the geomet-
ric mean of five housekeeping genes including Cltc, Gapdh, Gusb,
Hprt1, and Tubb5. Out of 529 genes analyzed, 58 genes were signifi-
cantly upregulated and 58 genes were downregulated. Strikingly,
genes most strongly upregulated in Grn/ microglia are those previ-
ously described for MGnD (Fig 1A; Butovsky et al, 2015; Holtman
et al, 2015; Keren-Shaul et al, 2017; Krasemann et al, 2017). These
include ApoE, as the most upregulated gene, Ly9, Clec7a, Dnajb4,
Cccl4, and many others suggesting that PGRN-deficient microglia
adopt the MGnD state. We then compared the Grn/ microglial
signature to the previously analyzed molecular signature of Trem2/
microglia (Fig 1B and C; Mazaheri et al, 2017). Both NanoString gene
expression panels overlapped in 418 genes. Out these, 359 mRNAs
could be detected in both screens (Dataset EV1). In the Grn/ micro-
glia, 40 mRNAs were upregulated and 55 mRNAs were downregu-
lated, whereas in the Trem2/ microglia, 87 mRNAs were increased
and 27 mRNAs were decreased (Fig 1C; left two panels). Interestingly,
while only six mRNAs were equally up/downregulated in both pheno-
types, 32 mRNAs showed an opposite regulation (Fig 1C; right panel).
Strikingly, while in Grn/ mice the neurodegenerative disease-asso-
ciated signature is massively upregulated, this set of genes is
suppressed in the Trem2/ microglia (Fig 1B and D; Mazaheri et al,
2017). Similarly, the homeostatic mRNA signature is slightly but
significantly upregulated in Trem2/ microglia (Mazaheri et al,
2017) but severely suppressed in Grn/ microglia (Fig 1B and D).
Confirmation of molecular microglial signatures on protein level
Expression of proteins associated with MGnDs such as ApoE,
CLEC7A, TREM2, and CD68 was also increased in acutely isolated
microglia (Fig 2A and B). sTREM2 was also found to be increased in
brains and serum of Grn/ mice (Fig 2C and D), although no
increase in Trem2 mRNA levels was observed in the NanoString
analysis (Fig 1B), suggesting posttranscriptional regulation.
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Furthermore, protein expression of the homeostatic P2ry12 gene is
downregulated in cortical Grn/ microglia (Fig 2E and F), while
cortical microglia from Trem2/ mice show strongly elevated
P2RY12 levels (Fig 2E and F), consistent with the finding that micro-
glia from both mouse models are in opposite activation states. These
findings were further confirmed in genetically modified BV2 micro-
glia-like cells lacking PGRN expression, where ApoE, CLEC7A, and
TREM2 were upregulated, whereas P2RY12 was downregulated
(Fig 2G–I). In line with the protein expression, in PGRN-deficient
BV2 cells, transcripts encoding Apoe, Clec7a, and Trem2 were also
significantly upregulated, whereas P2ry12 was downregulated
(Fig 2J) further confirming that loss of PGRN results in a microglial
hyperactivation.
Increased phagocytic capacity, chemotaxis, and clustering
around amyloid plaques upon loss of PGRN
Next, we investigated a series of functional phenotypes in Grn loss-
of-function mutants, which may be differentially affected by dysreg-
ulated Trem2 or Grn gene expression. First, we investigated the
phagocytic capacity of PGRN-deficient BV2 cells, which recapitulate
expression profile changes found in isolated Grn/ microglia such
as enhanced expression of ApoE, CLEC7A, and TREM2 (Fig 2). We
observed a significantly increased uptake of pHrodo-labeled Escheri-
chia coli (E. coli) in PGRN-deficient BV2 cells compared to wt
(Fig 3A). Enhanced uptake of pHrodo-labeled bacteria is in strong
contrast to the reduced uptake detected in Trem2 loss-of-function
mutations (Fig EV1A; Kleinberger et al, 2014, 2017; Schlepckow
et al, 2017), thus demonstrating that differentially regulated mRNA
signatures translate into opposite phagocytic phenotypes. In acutely
isolated microglia, uptake of bacteria was also reduced upon loss of
TREM2 (Fig EV1B). Grn/ microglia displayed only a slight but
significant increase in phagocytosis (Fig EV1B). The rather minor
effect of the Grn knockout on increased microglial phagocytosis
is most likely due to isolation-induced activation of microglia
(Gosselin et al, 2017), which as a consequence already show a
rather high uptake capacity.
Previously, we demonstrated that microglia of Trem2/ mice
are locked in a homeostatic state and fail to migrate (Mazaheri et al,
2017). Since microglia of Grn/ mice express a RNA profile typical
for MGnD, we investigated if that results in increased migration. To
assess migration ex vivo, we cultured organotypic brain slices from
young (P6-7) mice as recently described (Daria et al, 2017; Maza-
heri et al, 2017). In line with our previous findings, we found only
baseline migration of wt microglia reflected by few migrating CD68-
positive cells detected mainly in the vicinity of the brain tissue
(Fig 3B–D). On the contrary, the number of migrating CD68-positive
cells and their distance migrated were both significantly increased
in brain slices derived from the Grn/ mice (Fig 3B–D). Again, this
finding is in clear contrast to our previous observation in cultured
▸Figure 2. Expression of microglial marker protein characteristic for the homeostatic or disease-associated state.A Immunoblot analysis of ApoE, CLEC7A, TREM2, and CD68 in lysates of acutely isolated microglia from Grn/ and Grn+/+ mice (9 months of age, n = 3 per genotype,
female). IBA1 was used as loading control. The asterisk indicates an unspecific band.
B Quantification of protein expression normalized to levels of Grn+/+ microglia (n = 3). Data represent the mean  SD.
C ELISA-mediated quantification of sTREM2 in brain homogenates of Grn/ and Grn+/+ mice. Data are shown as mean  SEM (n = 3–6).
D ELISA-mediated quantification of sTREM2 in serum of Grn/ and Grn+/+ mice. Data are shown as mean  SEM (n = 4–13).
E Microglial expression of P2RY12 in cortical sections of wt, Grn/ and Trem2/ mice. (9 months of age, female). Scale bar indicates 10 lm.
F Quantification of P2RY12-positive microglia. Data are shown as mean  SD (n = 3 per genotype, female, except one male for Trem2/).
G Immunoblot analysis of secreted PGRN and ApoE (ApoEmed) in conditioned media and PGRN, ApoE, CLEC7A, P2RY12, and TREM2 in lysates of BV2 wild-type (Grnwt)
and PGRN-deficient (Grnmut) cells. Soluble amyloid precursor protein (APPs) and calnexin were used as a loading control. The asterisk indicates an unspecific band.
H Quantification of immunoblots normalized to BV2 Grnwt levels (n = 3–5). Data represent the mean  SD.
I ELISA-mediated quantification of sTREM2 in conditioned media of BV2 Grnwt and Grnmut cells. Data represent the mean  SD (n = 4).
J Quantification of relative mRNA levels of Apoe, Clec7a, P2ry12, and Trem2 in BV2 Grnwt and Grnmut cells. Data represent the mean  SD (n = 3).
Data information: For statistical analysis, unpaired two-tailed Student’s t-test was performed between Grnmut or Grn
/ in comparison with Grnwt or Grn
+/+: n.s., not
significant; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001. For (F), the one-way ANOVA with Tukey post hoc test was used.
Source data are available online for this figure.
◀ Figure 1. Opposite mRNA signatures of Grn//Trem2+/+ and Trem2//Grn+/+ microglia.A Volcano blot representation of the differently expressed genes in FCRLS- and CD11b-positive Grn/ microglia in comparison with wt microglia isolated from
5.5-month-old mice (male, n = 5). 116 genes out of 529 genes analyzed are significantly changed, and from these, 58 genes are upregulated and 58 genes are
downregulated. Eight up- and down regulated genes with the highest fold change are indicated.
B Heatmap of significantly affected genes (P < 0.05) in FCRLS- and CD11b-positive Grn/ microglia in comparison with Grn+/+ microglia isolated from 5.5-month-old
mice (n = 5 per genotype). For the significantly affected genes of the Grn/ microglia, mRNA expression data of the Trem2/ microglia in comparison with the
corresponding wt microglia were taken from previously published data (Mazaheri et al, 2017). The RNA counts for each gene and sample were normalized to the
mean value of wt followed by a log2 transformation (n ≥ 5 per genotype). *labeled genes were not analyzed or below detection limit in Trem2/ microglial mRNA
expression dataset (Mazaheri et al, 2017).
C Changes in gene expression of 359 detected genes in Grn/ microglia and Trem2/ microglia. Note that from the 38 genes significantly altered in both genotypes, 32
genes are regulated in opposite direction.
D Expression levels of significantly altered homeostatic and MGnD genes of Grn/ and Trem2/ microglia from the data set in (B). Gene expression is normalized to
the mean of the wt cohort in comparisons with the published normalized dataset of Trem2/ microglia (Mazaheri et al, 2017). Data represent the mean +/ SD.
Data information: For statistical analysis, unpaired two-tailed Student’s t-test was performed between Grn/ microglia in comparison with Grn+/+ microglia or Trem2/
microglia in comparison with Trem2+/+ microglia: not significant P > 0.05; *P < 0.05; **P < 0.01; and ***P < 0.001.
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Figure 3. Enhanced phagocytosis, migration, and clustering around amyloid plaques upon PGRN deficiency.
A Flow cytometric analysis of phagocytic capacity in BV2wt and BV2mut cells using pHrodo green E. coli as target particles. Phagocytosis was terminated after 30 and
60 min (min) of incubation. Data are presented as mean percentage of cells positive for pHrodo uptake  SD (n = 3).
B Enhanced migration of CD68-positive, PGRN-deficient cells in an ex vivo model. Immunofluorescence analysis of cultured Grn+/+ and Grn/ organotypic brain at 7
DIV immunostained using microglial marker CD68. Nuclei were counterstained using DAPI. Images of boxed regions in left panels are shown at higher magnifications
in right panels. Scale bars: 500 lm (left panels), 250 lm (right panels).
C Quantitative analysis reveals that Grn/ microglia migrate larger distances than Grn+/+. Data are shown as mean  SD (n = 3 independent experiments).
D Quantification displays an increased number of migrating Grn/ cells compared to Grn+/+ cells. Data are shown as mean  SD (n = 3 independent experiments).
E Enhanced microglial clustering around amyloid plaques in the absence of PGRN. Left: IBA1-stained microglial clustering around X-34-positive amyloid plaque cores in
4-month-old APPPS1/Grn+/+ mice. Right: Age-matched APPPS1/Grn/ mice display microglial hyper-clustering around amyloid plaques compared with APPPS1/Grn+/+.
Dotted white boxes indicate the area that is shown at higher magnification. Scale bars indicate 10 and 3 lm in inset.
F Immunohistochemical quantification of IBA1-positive microglial cell number per plaque (APPPS1/Grn+/+ n = 4, APPPS1/Grn/ n = 4; 4-month-old; two males and
two females per genotype) normalized to APPPS1/Grn+/+ mice. Approximately 20–50 amyloid plaques were counted per mouse in 3 cortical sections to calculate the
number of IBA1-positive microglia per plaque. Data are shown as mean  SD.
Data information: For statistical analysis, unpaired two-tailed Student’s t-test was performed (A, C, D) between PGRN-deficient Grnmut BV2 cells or Grn
/ microglia and
Grnwt BV2 cells or Grn
+/+ microglia. For (F) the Mann–Whitney U-test, two-tailed analysis was used. Significance is indicated by *P < 0.05; **P < 0.01; and ***P < 0.001.
Source data are available online for this figure.
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organotypic brain slices derived from Trem2/mice, where we found
a severe inhibition of migration as compared to wt (Mazaheri et al,
2017). The increasedmigratory potential is in line with enhanced clus-
tering of IBA1-positive microglia that we detected around amyloid
plaques in APPPS1/Grn/ versus APPPS1/Grn+/+mice (Figs 3E and
F, and EV1C). Again, this finding is opposite to what was found in the
absence of functional TREM2, namely impaired clustering ofmicroglia
around amyloid plaques (Wang et al, 2016; Parhizkar et al, 2019) and
a general reduction of chemotaxis (Mazaheri et al, 2017).
Increased TSPO-PET signals in Grn/ mice and a human patient
with GRN haploinsufficiency
To confirm that our findings have relevance in vivo, we searched for
differences in microglial activity between Trem2/ and Grn/
mice by previously established in vivo TSPO-lPET imaging (Liu
et al, 2015; Kleinberger et al, 2017). In line with the hypothesis
gained from in vitro experiments, we observed a striking upregula-
tion of microglial activity throughout the cerebrum of Grn/ mice
when compared to wt (Fig 4A). Differences were pronounced in the
neocortex but also present in subcortical areas. On the contrary, a
reduced microglial activity was apparent in the entire cerebrum of
Trem2/ mice, fitting to our recent findings in a TREM2 loss-of-
function model (Kleinberger et al, 2017; Fig 4A).
Furthermore, we translationally investigated a FTLD patient with
a genetically confirmed GRN (NM_002087.2) loss-of-function muta-
tion (c.328C>T, p.(Arg110*)). Haploinsufficiency of PGRN was
proven by ELISA-mediated quantitative analysis of the patient’s
serum (Fig 4B). TSPO-PET imaging revealed elevated cortical micro-
glial activity in comparison with a FTLD patient screened negative



























































































Figure 4. Enhanced microglial activity in Grn/ mice and in a patient with Grn haploinsufficiency.
A TSPO-lPET in rodents: Axial slices (A1, A2, A3) of averaged %-TSPO-PET differences between Grn/ or Trem2/ mice and wt indicate increased microglial activity in
the cerebrum of Grn/ mice (hot color scale) and decreased microglial activity in the cerebrum of Trem2/ mice (cold color scale). Scatter plot depicts single TSPO-
lPET values deriving from a neocortical volume of interest. Data represent the mean +/ SD. lPET results are illustrated upon an MRI template; 6–10 female mice per
group (Grn/ n = 6 at 8 months, Trem2/ n = 8 at 11 months; wt n = 10 at 8–11 months). Statistics were derived from one-way ANOVA with Tukey post hoc test.
B PGRN serum levels of the patients subjected to TSPO-PET confirmed the GRN mutation and non-GRN mutation carrier. PGRN was measured by ELISA in technical
triplicates and normalized to serum levels of a healthy control. Data represent the mean +/ SD.
C TSPO-PET in human FTLD patients: Visual interpretation of axial TSPO-PET SUVR images in upper cranial layers reveals increased microglial activity in frontal and
parietal cortices (white arrows) of a FTLD patient with a GRN loss-of-function mutation in comparison with a FTLD patient without a GRN mutation. PET results are
illustrated upon an MRI template; 60–80 min p.i. emission recording; and global mean scaling. Both patients were low-affinity binder.
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Cerebral hypometabolism upon loss of PGRN and TREM2
Next, we investigated whether alterations of microglial activity have
an impact on synaptic brain function as assessed by in vivo FDG-
lPET. We observed a cerebral hypometabolism not only in
Trem2/ mice, which had been anticipated from our previous
study (Kleinberger et al, 2017), but even more severe in Grn/
mice (Fig 5). As activated microglia itself could lead to increased
energy consumption, the results in Grn/ mice appear even more
striking. Thus, a failure of brain function was confirmed as a conse-
quence of both, arresting microglia in a homeostatic and a disease-
associated stage.
Discussion
Taken together, our findings demonstrate that microglia lacking
functional TREM2 or PGRN exhibit opposite mRNA profiles. This is
consistent with the differential TSPO-PET signal observed in both
animal models. While Grn/ mice exhibit a hyperactivated pheno-
type, which is consistent with the observation that Grn/ mice
exhibit an exaggerated inflammation (Yin et al, 2010; Martens et al,
2012; Tanaka et al, 2013a; Lui et al, 2016) as well as induced
expression of TYROBP network genes including Trem2 (Takahashi
et al, 2017), TREM2 loss of function results in reduced microglial
activity. As a consequence, several functional assays including
phagocytic capacity, migration, and chemotactic clustering around
amyloid plaques revealed opposite phenotypes. Thus, loss of PGRN
or TREM2 arrests microglia at the two extreme ends of a potential
gradient of dynamic microglial populations (Fig 6; upper panel).
Nevertheless, in both animal models we observed a dramatic reduc-
tion of glucose metabolism throughout the brain and loss of either
protein causes severe neurodegeneration in humans. Reduced
energy metabolism in Trem2/ mice is in line with previous
observations (Kleinberger et al, 2017; Ulland et al, 2017). Thus, it is
tempting to speculate that microglia on the opposite ends of a large







































Figure 5. Cerebral hypometabolism upon loss of GRN and TREM2.
FDG-lPET in rodents: Axial slices (as indicated in Fig 4A) of averaged %-FDG-lPET differences between Grn/ or Trem2/ mice and wt indicate decreased glucose
metabolism in the cerebrum of Grn/ and Trem2/ (both cold color scales) when compared to wt. Scatter plot depicts single FDG-PET values deriving from a neocortical
volume of interest. Data represent the mean +/ SD. lPET results are illustrated upon an MRI template; 6–10 female mice per group (Grn/ n = 6 at 8 months, Trem2/
n = 6 at 11 months; wt n = 10 at 8–11 months). Statistics were derived from one-way ANOVA with Tukey post hoc test.
TREM2 LOF PGRN LOF 
homeosta c sig. disease sig.therapeuticwindow
NEURODEGENERATION
homeosta c sig. disease sig.
TREM2 LOF
homeosta c sig. disease sig.
PGRN LOF 
homeosta c sig. disease sig.
THERAPEUTIC MODULATION
Figure 6. Modulation of microglia activity states within a narrow
therapeutic window.
Schematic presentation of the disease-associated/homeostatic phenotypes
observed in Grn/ mice versus Trem2/ and the potential consequences for a
therapeutic window of microglial modulation.
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neurological dysfunctions that ultimately may result in neurodegen-
eration. In fact, disease-associated variants of TREM2 are associated
with a loss of a protective function of TREM2 (Kleinberger et al,
2017; Song et al, 2018) and some mutations appear to lock micro-
glia in a homeostatic stage (Krasemann et al, 2017; Mazaheri et al,
2017). On the other hand, during aging wild-type microglia in an
AD mouse model lose their motility and phagocytic activity (Krabbe
et al, 2013) although they express a neurodegenerative disease-asso-
ciated mRNA profile (Krasemann et al, 2017). This may indicate
that “over-activation” for a prolonged period of time may be detri-
mental for microglia and drive them into a loss-of-function pheno-
type. Our findings also indicate that arresting microglia in either a
homeostatic state or a disease-associated state would be equally
detrimental. This has important consequences for therapeutic strate-
gies aiming to modulate microglial activity. Clearly, locking micro-
glia in any of the two extreme states is detrimental (Fig 6, upper
panel). Rather, microglia locked in a homeostatic state should be
activated whereas microglia arrested in a disease-associated state
may be silenced (Fig 6, lower panel). Nevertheless, during long-
term treatment “over-activation” and “over-silencing” of microglia
may both be equally detrimental, since that may drive microglia
to the opposite ends of the gradient. As a consequence, the
therapeutic window for microglial modulation may be rather




All animal experiments were performed in accordance with local
animal-handling laws. Housing conditions included standard pellet
food and water provided ad libitum, 12-h light–dark cycle at tempera-
ture of 22°C with maximal 5 mice per cage and cage replacement once
per week, and regular health monitoring. Mice were sacrificed by CO2
inhalation. Brain tissue, microglia, and serum were obtained from the
Grn/ mouse strain (Kayasuga et al, 2007), brain tissue and microglia
were obtained from the Trem2/ mouse strain (Turnbull et al, 2006),
and brain tissue was obtained from a mouse model for amyloid pathol-
ogy (APPPS1; Radde et al, 2006) crossed with the Grn/ mouse strain
(APPPS1/Grn/). Experiments were performed with mice of both
genders at 2–18 months of age. Organotypic brain slices were taken
from postnatal days 6–7 of Grn/ and wt mice.
Gene expression profiling
FCRLS (Butovsky et al, 2014)- and CD11b (BD biosciences; Clone
M1/70)-positive primary microglia were isolated from mouse brains
of 5.5 months of Grn/ and wt mice (n = 5 per genotype, male) as
described (Mazaheri et al, 2017). Total RNA was isolated using
mirVanaTM miRNA Isolation Kit (Ambion) according to the manu-
facturer’s protocol. 100 ng RNA per sample was used for gene
expressing profiling using nCounter Analysis, NanoString technol-
ogy as described (Butovsky et al, 2014, 2015). In brief, the MG534
NanoString chip was designed using the quantitative NanoString
nCounter platform. Selection of genes is based on analyses that
identified genes and proteins, which are specifically or highly
expressed in adult mouse microglia (Butovsky et al, 2014) and
encompasses 400 homeostatic unique and enriched microglial genes
(Butovsky et al, 2014), 129 disease-associated genes, and 5 house-
keeping genes (Krasemann et al, 2017).
Data normalization and analysis
NanoString data were normalized and analyzed using nSolverTM soft-
ware. RNA ncounts were normalized using the geometric mean of
five housekeeping genes including Cltc, Gapdh, Gusb, Hprt1, and
Tubb5 using nSolverTM Analysis Software, version 3.0 (NanoString
Technologies, Inc.). A cutoff was introduced at the value two-fold of
the highest negative control present on the chip. Fold changes were
calculated using the average of each group. For each experiment, the
fold changes were calculated comparing the experimental group to
their appropriate controls. To compare the normalized gene expres-
sion levels in Grn/ and wt mice, unpaired two-tailed Student’s
t-test was performed (*P < 0.05, **P < 0.01, ***P < 0.001). The
volcano blot was generated employing GraphPad Prism 7 software.
The heatmap was generated employing Multi Experiment Viewer v
4.9. The expression value for each gene was normalized to the mean
value of wt mice followed by a log2 transformation.
sTREM2 ELISA analysis of mouse plasma and brain samples
Blood collected from Grn/ and wt mice (3, 6, 13, 16–18 months of
age, female and male mice as indicated in the source data file to
Fig 2) was left at room temperature (RT) to allow the blood to clot.
After centrifugation (15 min, 2,000 × g, RT), the supernatant (serum)
was collected, snap-frozen in liquid nitrogen, and stored at80°C.
Snap-frozen mouse brain hemispheres were homogenized by
crunching the brain in liquid nitrogen to fine powder. Approxi-
mately 10–20 mg of powdered mouse brain from Grn/ and wt
mice (3–4, 6, 13, 16–18 months of age, female and male mice as
indicated in the source data file to fig 2) was homogenized in Tris-
buffered saline (TBS) supplemented with protease inhibitor cocktail
(Sigma-Aldrich) and centrifuged for 30 min, 15,000 × g, 4°C.
Protein concentrations of supernatants were determined using the
BCA protein assay (Pierce, Thermo Scientific), and equal amount of
protein was analyzed for TREM2. sTREM2 levels in mouse serum or
mouse brain extracts were quantified using the Mesoscale platform
essentially as described previously (Kleinberger et al, 2017) using
0.25 lg/ml biotinylated polyclonal goat anti-mouse TREM2 (R&D
Systems; BAF1729) as capture antibody and 1 lg/ml rat monoclonal
anti-TREM2 antibody (R&D Systems, MAB17291) as detection anti-
body. Calculation of the concentration of sTREM2 was performed
with the MSD Discovery Workbench v4 software (MSD).
Cell culture and CRISPR/Cas9 genome editing in BV2 cells
The murine microglial cell line BV2 (Bocchini et al, 1992) was
maintained in Dulbecco’s modified Eagle’s medium (DMEM) +
GlutaMAXTM- I (Thermo Fisher Scientific, 61965-026) supplemented
with 10% (v/v) FBS (Sigma-Aldrich, F7524), 100 U/ml penicillin,
and 100 lg/ml streptomycin. For genome editing, BV2 cells were
transfected with pSpCas9(BB)-2A-GFP (PX458; gift from Feng Zhang
(Ran et al, 2013), targeting exons 3 and 4 with the gRNA1 ATAAC
GAGCCATCATCTAGA and gRNA2 GGCTTCCACTGTAGTGCAGA;
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Addgene plasmid #48138) by electroporation with the Cell Line
Nucleofector Kit T (Lonza VACA-1002) following the manufac-
turer’s instructions. GFP-positive cells were isolated by FACS 24 h
after transfection. Single-cell clones from the GFP-positive fraction
were obtained by serial dilution and screened for genetic modifi-
cations in Grn by PCR amplification of exons 3 and 4. Media and
lysates of edited clones were analyzed by Western blot for PGRN
expression.
Quantitative real-time PCR (qRT–PCR)
Total RNA was prepared from BV2 cells using the QIAshredder
and RNeasy Mini Kit (Qiagen) according to manufacturer’s instruc-
tions. 2 lg of RNA was reverse transcribed into cDNA using M-
MLV reverse transcriptase (Promega) and oligo(dT) primers (Life
Technologies). The following primer sets from Integrated DNA
Technologies were used: mouse Trem2 Mm.PT.58.46092560 (Exon
boundary 2 to 4b), mouse Apoe Mm.PT.58.33516165 (Exon bound-
ary 1 to 3), Clec7a Mm.PT.58.42049707 (Exon boundary 1 to 2),
and P2ry12 Mm.PT.58.43542033 (Exon boundary 3 to 4). cDNA
levels were measured in triplicates using TaqMan assays on a
7500 Fast Real-Time-PCR System (Applied Biosystems), normalized
to Gapdh cDNA expression, and relative transcription levels of the
respective sequences were analyzed using the comparative delta
Ct method (7500 Software V2.0.5, Applied Biosystems, Life
Technologies).
Isolation of adult primary microglia for immunoblotting
Primary microglia were isolated from adult mouse brain (9 months
of age, n = 3 per genotype, female) using MACS Technology (Mil-
tenyi Biotec) according to manufacturer’s instructions as described
previously (Gotzl et al, 2018).
Cell lysis and immunoblotting
Snap-frozen cell pellets were lysed in RIPA lysis buffer followed by
centrifugation at 17,000 × g, 4°C for 20 min [RIPA lysis buffer
(150 mM NaCl, 20 mM Tris–HCl pH 7.4, 1% NP-40, 0.05% Triton
X-100, 0.5% sodium deoxycholate, 2.5 mM ETDA)]. Protein concen-
trations were determined using the BCA protein assay (Pierce,
Thermo Fisher Scientific), and equal protein amounts were analyzed
in SDS–PAGE. For the detection of PGRN, TREM2, CLEC7A,
P2RY12, calnexin, CD68, IBA1, and APP gels were transferred on
polyvinylidene difluoride membranes (Amersham Hybond P 0.45
PVDF, GE Healthcare Life Science). For the detection of ApoE, nitro-
cellulose membranes were used (GE Healthcare Life Science).
Membranes were blocked for 1 h in I-BlockTM (Thermo Fisher Scien-
tific) and exposed to the following antibodies. In-house antibodies
were as follows: PGRN (Rat 8H10 1/50; Gotzl et al, 2014) and
TREM2 (Rat 5F4 1/50; (Xiang et al, 2016)). Commercial antibodies
were as follows: CLEC7A (R&D Systems, AF1756, 1/2,000), P2RY12
(Abcam, [EPR18611] (ab184411), 1/1,000) and ApoE (Merck,
AB947, 1/2,000), and APPs (Merck, MAB348 clone 22C11, 1/5,000).
For immunoblotting in primary microglia: ApoE (HJ6.3, 1/700),
kindly provided by David E. Holtzman (Kim et al, 2012), CD68
(Abcam, ab125212, 1/1,000), and IBA1 (GeneTex, GTX100042,
1/1,000) were used. HRP-conjugated secondary antibodies and ECL
Plus (PierceTM, Thermo Fisher Scientific) were used for detection.
For the quantitatively analysis, images were taken by a Luminescent
Image Analyzer Vilber/Peqlab Fusion SL and evaluated with the
Multi Gauge V3.0 software (Fujifilm Life Science, Tokyo, Japan).
Phagocytosis assay
Assays to determine the phagocytic capacity were carried out as
described before (Kleinberger et al, 2014, 2017). Briefly, BV2 cells
were seeded at a density of 100,000 cells per well of a 12-well dish
and 1 day after seeding, incubated with pHrodo green E. coli for 30
and 60 min at 37°C after (pHrodo Green E. coli BioParticles
Thermo Fisher). To analyze E. coli uptake, cells were resuspended
in FACS buffer (PBS, 2 mM EDTA and 1% FBS) and subjected to
flow cytometry. Data were acquired using the MACSQuant.
Cytochalasin D was used as an uptake inhibitor at a final concentra-
tion of 10 lM. Phagocytosis assays with primary microglia were
performed similar to BV2 cells with the following modifications:
Cells were isolated from adult mouse brain (2 months of age, n = 3
per genotype, male) as described above. Following isolation,
primary microglia were cultivated in DMEM/F-12 (Thermo Fisher
Scientific, 31330-038) supplemented with 10% (v/v) FBS (Merck,
Sigma-Aldrich), 100 U/ml penicillin, 100 lg/ml streptomycin, M-
CSF (10 ng/ml), and TGF-b (50 ng/ml). Four days after seeding at a
concentration of 100,000 cells per well of a 24-well plate, cells were
incubated with pHrodo for 45 min at 37°C. APC-CyTM7 Rat Anti-
CD11b (BD PharmingenTM, M1/70, 557657, 1/100) was used as a cell
population control.
Ex vivo migration assay
Organotypic brain slices from postnatal days 6–7 of Grn/ and wt
mice were prepared, cultured, and immunostained as described
before (Daria et al, 2017; Mazaheri et al, 2017). Microglial migra-
tion was analyzed after 7 days ex vivo as described (Daria et al,
2017; Mazaheri et al, 2017). Quantification was performed in three
independent experiments, each including three biological replicates
(three independent slice culture dishes per animal and genotype).
From each biological replicate, three defined image regions
(775 × 775 lm) of the cortical area in the brain slice were acquired
using a Leica SP5 confocal microscope with a 20× dry objective. Tile
scan images were captured using a 10× dry objective. The number
of migrating CD68-positive microglia and the maximum distance
migrated were quantified using Fiji. The migration distance
measurements (average of three length measurements per acquired
image) were performed on an area defined by two manually drawn
lines, one limiting the boarder of the tissue and the other surface
covered by at least 90% of migrated microglial cells.
Immunohistochemistry and image analysis
Following deparaffinization and rehydration of paraffin-embedded
brain sections, tissue sections mounted on slides were subjected to
citric acid antigen retrieval (1 M sodium citrate in PBS, pH 6.0) and
boiled in a microwave for 20 min. After cooling, sections were
blocked with 5% donkey serum for 1 h at room temperature. Follow-
ing this, sections were incubated with primary antibodies against
IBA1 (Invitrogen, Thermo Fisher Scientific, 1/300) and b-amyloid
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(Biolegend, 6E10, 1/300) over two nights at 4°C. Subsequently,
sections were washed and incubated with secondary antibodies
(donkey anti-rabbit Alexa Fluor 488, 1/700, donkey anti-mouse
Alexa Fluor 555, 1/1,000, respectively) overnight at 4°C. For the
P2RY12 co-stainings, brains of 9-month-old female mice (except one
male for Trem2/, n = 3 per genotype) were immerse-fixed in 4%
PFA for 24 h following perfusion. Brains were subsequently cryopro-
tected in 30% sucrose for 48 h. After freezing, 50-lm-thick micro-
tome sections were sequentially collected in phosphate buffer saline
with 15% glycerol and kept at 80°C until further use. Free-floating
sections were blocked in 5% goat serum for 1 h at room temperature
and then incubated in primary antibodies P2RY12 (Biolegend,
1/100) and IBA1 (Invitrogen, Thermo Fisher Scientific, 1/300) for
two nights at 4°C. Sections were washed and incubated in secondary
antibodies (goat anti-rat Alexa Fluor 555, 1/500, goat anti-rabbit
Alexa Fluor 488, 1/500) for 3 h at room temperature. Lastly, slides
were washed and stained with 40,6-diamidino-2-phenylindole (DAPI,
5 lg/ml) before mounting coverslips with ProlongTM Gold Antifade
reagent (Thermo Fisher Scientific). Images were acquired using a
LSM 710 confocal microscope (Zeiss) and the ZEN 2011 software
package (black edition, Zeiss). Laser and detector settings were
maintained constant for the acquisition of each immunostaining. For
analyses, three images were taken per slide using 20× objective
(Plan-Apochromat 20×/0.8 M27) at 2,048 × 2,048 pixel resolution,
with Z-step size of 1 lm at 16 lm thickness. Approximately 150
plaques per genotype were counted using FIJI software (ImageJ) to
calculate the number of IBA1-positive microglia around plaques in
the cortex. Microglia coverage was quantified by importing acquired
images to FIJI, and data channels were separated (Image\Color\Split
Channels). Gaussian filtering was used to remove noise, and inten-
sity distribution for each image was equalized using rolling ball algo-
rithm, which is implemented as background subtraction plug-in in
FIJI. For the feasibility of the quantification, all layers from a single
image stack were projected on a single slice (Stack\Z projection).
Next, the microglia were segmented using automatic thresholding
methods in Fiji with “Moments” thresholding setting. Subsequently,
the diameter (25 or 50 lm) around each plaque was selected to
calculate the sum number of positive pixels over total number of
pixels within the selected area. Data for 50 lm were subtracted from
25 lm to calculate the microglia coverage in the periphery of the
plaque only. Data were normalized to age-matched APPPS1/Grn+/+
or Grn+/+ controls (4-month-old mice; two males and two females
per genotype).
Rodent lPET
All rodent lPET procedures followed an established standardized
protocol for radiochemistry, acquisition, and post-processing
(Brendel et al, 2016; Overhoff et al, 2016). In brief, 18F-GE180 lPET
with an emission window of 60–90 min p.i. was used to measure
cerebral microglial activity and 18F-fluordesoxyglucose (FDG) PET
with an emission window of 30–60 min p.i. was used for assess-
ment of cerebral glucose metabolism. We studied Grn/ mice
(n = 6; female, 8 months), Trem2/ mice (n = 6–8; female,
11 months), and wt mice (n = 7–10; female, 8–11 months) by dual
PET. Normalization of injected activity was performed by the previ-
ously validated myocardium correction method (Deussing et al,
2017) for TSPO-PET and by percentage of the injected dose (%-ID)
for FDG-PET. Known changes in TSPO and FDG-PET during aging
(Brendel et al, 2017) were accounted to compensate for natural
age differences between individual mice. Groups of Grn/ and
Trem2/ mice were averaged and compared against wt mice by
calculation of %-differences in each cerebral voxel. Finally, TSPO
and FDG-PET values deriving from a cortical target VOI
(Rominger et al, 2013) were extracted and compared between
groups of different genotype by a one-way ANOVA including
Tukey post hoc correction.
Patient identification, genetic studies, PGRN ELISA, and PET
Written informed consent was obtained from all subjects prior to
PET examination, and the experiments conformed to the principles
set out in the World Medical Association (WMA) Declaration of
Helsinki on ethical principles for medical research and the Depart-
ment of Health and Human Services Belmont Report.
A female patient, 63 years at date of PET, presented with primary
progressive aphasia with semantic and non-fluent features. Genetic
testing was performed because of a positive family history (triplet
brother with early-onset dementia). Exome sequencing from blood
DNA and data analysis was performed as described before (Kremer
et al, 2017). In brief, exonic regions were enriched using the SureS-
elect Human All Exon Kit V6 from Agilent followed by sequencing
as 100 bp paired-end runs on an Illumina HiSeq4000 (Illumina, San
Diego, CA, USA) to an average read depth of 144x. Reads were
aligned to the UCSC human reference assembly (hg19) with
Burrows–Wheeler algorithm (BWA v.0.5.9). More than 98% of the
target sequences were covered at least 20× in all samples. Single
nucleotide variants (SNVs) as well as small insertions and deletions
were detected with SAM tools v.0.1.19. In-house custom Perl scripts
were used for variant annotation. PGRN serum levels measured by
ELISA confirmed the GRN mutation carrier. PGRN levels were
measured and quantified using the Mesoscale platform essentially
as described previously (Capell et al, 2011) using a biotinylated
polyclonal goat anti-human PGRN antibody at 0.2 lg/ml (R&D
Systems; BAF2420) as capture antibody and a monoclonal mouse
anti-human PGRN antibody at 0.25 lg/ml for detection (R&D
Systems, MAB2420). Calculation of the concentration of PGRN was
performed with the MSD Discovery Workbench v4 software (MSD).
Prior to PET in the patient, the affinity of the TSPO receptor for
binding of PET radioligands was assessed by determining the geno-
type of the SNP rs6971 as previously described (Mizrahi et al, 2012;
Owen et al, 2012).
The patient was scanned at the Department of Nuclear Medicine,
University hospital of Munich, by an established TSPO-PET protocol
(Albert et al, 2017). In brief, PET was acquired with a PET/CT scan-
ner (Biograph 64, Siemens) 60–80 min after intravenous injection of
187 MBq of 18F-GE180. A low-dose CT scan preceded the PET acqui-
sition and served for attenuation correction. An SUVR image was
generated by a global mean scaling and compared visually with
TSPO-PET data deriving from a 56-year-old female patient with
bvFTD, indicating no mutation in GRN and the same binding affinity
status. This patient was scanned secondary to informed consent
following the same TSPO-PET scanning procedure. In this patient,
mutations in GRN, TREM2, and MAPT were excluded by panel
sequencing as well as the C9orf72 hexanucleotide expansion by
repeat-primed PCR.
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Statistical analysis
All data were analyzed using GraphPad Prism 7. Data are presented as
mean  SD or SEM as indicated. Statistical significance was calculated
by unpaired two-tailed Student’s t-test (Figs 1A–D and 2B, C, D, H, I
and J, and 3A, C, D and EV1A and B), one-way ANOVA with Tukey’s
post hoc test (Figs 2F, 4A and 5) for multiple comparison, and the
nonparametric two-tailed Mann–Whitney U-test (Figs 3F and EV1C).
Statistical evaluations were displayed as follows: n.s. not significant
for P > 0.05; statistical significance was assumed at *P < 0.05;
**P < 0.01; ***P < 0.001; and ****P < 0.0001.
For the lPET experiments, animal numbers were calculated for a
significance of 0.05 and a power of 80%. Animal numbers were not
changed during the experiments, and no outliers were excluded
from datasets. For all experiments, the genotype was unknown to
the investigators.
Data availability
The datasets produced in this study are available in the following
databases:
• Pathogenic variant in GRN: ClinVar SCV000897721.1 (https://
www.ncbi.nlm.nih.gov/clinvar/?term=SCV000897721.1).
• NanoString gene sequence, raw, and processed data: Gene Expres-
sion Omnibus GSE129709 (https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE129709).
Expanded View for this article is available online.
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